Show simple item record

dc.contributor.authorBilgen, Hulya
dc.contributor.authorAnak, Sema
dc.contributor.authorOzdilli, Kursat
dc.contributor.authorBayram, Nihan
dc.contributor.authorNepesov, Serdar
dc.contributor.authorYaman, Yontem
dc.contributor.authorElli, Murat
dc.contributor.authorSahin, Sifa
dc.identifier.citationYaman Y., Elli M., Sahin S., Ozdilli K., Bilgen H., Bayram N., Nepesov S., Anak S., "Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience", PEDIATRIC TRANSPLANTATION, 2021
dc.description.abstractDelayed recovery of thrombocytopenia is a well-known complication after allogeneic HSCT. Eltrombopag (ELT), a thrombopoietin receptor agonist (TRAs), induces platelet maturation and release. Mostly conducted in adults, some of the previous studies have shown that ELT seems to enhance platelet recovery for post-allogeneic HSCT thrombocytopenia, appears efficacious, and offers transfusion independence. To evaluate the safety and efficacy of ELT in pediatric patients with prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) after alloHSCT. Retrospective analysis of childhood patients who received treatment with ELT for persistent thrombocytopenia after alloHSCT between May 2016 and August 2019. We evaluated the safety and efficacy of ELT in 18 childhood patients with PIT or SFPR after alloHSCT. Eltrombopag (50 mg/d) treatment was started in all patients, above 6 years of age and 20 kg weight, who had thrombocytopenia despite neutrophil engraftment on the 30th day of HSCT. Our objective was to decrease the need for platelet transfusion and have a platelet count of more than 50 000/mu L. The overall response rate was 77.7%. The median time to achieve a platelet level above 30 000/mu L and 50 000/mu L was 21 and 44 days, respectively. In four patients, platelet count never reached 30 000/mm(3). In two patients, the treatment was discontinued due to grade 3 hepatotoxicity. Our study supports the efficacy and relative safety of ELT use for the treatment of PIT and SFPR seen after alloHSCT in children.
dc.subjectÇocuk Sağlığı ve Hastalıkları
dc.subjectPediatrics, Perinatology and Child Health
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleEltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience
dc.contributor.departmentİstanbul Medipol Üniversitesi , ,

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record